Collegium Pharmaceutical (NASDAQ:COLL) Lowered to Buy Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Collegium Pharmaceutical from “strong-buy” to “buy” in a Saturday research note, though the stock still carries a generally positive analyst view.
• Across analysts, Collegium now has two Strong Buy ratings, three Buy ratings, and one Hold, with a consensus target price of $57.50.
• The company recently beat quarterly expectations, reporting $1.76 EPS versus $1.52 expected and $193.52 million in revenue versus $184.47 million expected, with revenue up 8.9% year over year.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued on Saturday.

COLL has been the subject of a number of other research reports. Zacks Research upgraded Collegium Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research note on Monday, June 29th. Weiss Ratings restated a "hold (c)" rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Finally, Truist Financial raised Collegium Pharmaceutical to a "strong-buy" rating in a research note on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of "Buy" and a consensus target price of $57.50.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $35.20 on Friday. The company has a market capitalization of $1.14 billion, a P/E ratio of 17.25 and a beta of 0.73. Collegium Pharmaceutical has a 1-year low of $29.19 and a 1-year high of $50.79. The firm's 50 day simple moving average is $34.65 and its two-hundred day simple moving average is $37.94. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.52 by $0.24. The firm had revenue of $193.52 million during the quarter, compared to analysts' expectations of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company's revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.49 earnings per share. Research analysts expect that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently bought and sold shares of COLL. Pacer Advisors Inc. boosted its holdings in shares of Collegium Pharmaceutical by 6.4% during the 1st quarter. Pacer Advisors Inc. now owns 256,365 shares of the specialty pharmaceutical company's stock valued at $8,478,000 after purchasing an additional 15,475 shares during the last quarter. NewEdge Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 113.1% in the first quarter. NewEdge Advisors LLC now owns 27,029 shares of the specialty pharmaceutical company's stock worth $894,000 after buying an additional 14,348 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Collegium Pharmaceutical by 52.5% in the first quarter. Bank of America Corp DE now owns 297,847 shares of the specialty pharmaceutical company's stock worth $9,850,000 after buying an additional 102,502 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Collegium Pharmaceutical by 26.0% during the first quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company's stock valued at $60,358,000 after buying an additional 377,073 shares during the last quarter. Finally, Smith Group Asset Management LLC grew its holdings in Collegium Pharmaceutical by 9.3% during the 1st quarter. Smith Group Asset Management LLC now owns 21,951 shares of the specialty pharmaceutical company's stock valued at $726,000 after buying an additional 1,865 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.